What is the major side effect associated with Vinblastine (Velban)?

What is the major side effect associated with Vinblastine (Velban)?

• A. Altered mental status
• B. Bone marrow suppression
• C. Renal toxicity
• D. Pulmonary fibrosis

Answer: (B)

Vinblastine (Velban) is a chemotherapeutic agent that is part of the vinca alkaloid class. A significant side effect associated with this medication is bone marrow suppression, which is the reduction in the ability of the bone marrow to produce blood cells. This suppression can lead to various complications such as anemia (due to low red blood cell count), increased risk of infection (due to low white blood cell count), and bleeding tendencies (due to low platelet count). Bone marrow suppression is a critical concern with many chemotherapeutic agents, and understanding this side effect is essential for managing patients receiving treatment with Vinblastine. Monitoring blood counts regularly during therapy is important to identify any significant drops in cell lineages, allowing timely intervention. This knowledge helps healthcare providers to mitigate risks and manage treatment-related complications effectively. In contrast, the other side effects listed are not primarily associated with Vinblastine. For instance, altered mental status can be caused by various factors but is not a direct side effect of Vinblastine. Renal toxicity is more associated with different types of chemotherapeutic agents, such as cisplatin, and pulmonary fibrosis is not a well-documented adverse effect of Vinblastine. Thus, focusing on bone marrow

Vinblastine (Velban) is a chemotherapeutic agent that is part of the vinca alkaloid class. A significant side effect associated with this medication is bone marrow suppression, which is the reduction in the ability of the bone marrow to produce blood cells. This suppression can lead to various complications such as anemia (due to low red blood cell count), increased risk of infection (due to low white blood cell count), and bleeding tendencies (due to low platelet count).

Bone marrow suppression is a critical concern with many chemotherapeutic agents, and understanding this side effect is essential for managing patients receiving treatment with Vinblastine. Monitoring blood counts regularly during therapy is important to identify any significant drops in cell lineages, allowing timely intervention. This knowledge helps healthcare providers to mitigate risks and manage treatment-related complications effectively.

In contrast, the other side effects listed are not primarily associated with Vinblastine. For instance, altered mental status can be caused by various factors but is not a direct side effect of Vinblastine. Renal toxicity is more associated with different types of chemotherapeutic agents, such as cisplatin, and pulmonary fibrosis is not a well-documented adverse effect of Vinblastine. Thus, focusing on bone marrow